Curewell Capital Acquires Majority Stake in Wilmington PharmaTech

Wilmington PharmaTech (WPT), a manufacturer of small molecule active pharmaceutical ingredients (API), has announced a significant development in its growth strategy. The company revealed that Los Angeles-based private equity firm Curewell Capital has acquired a majority stake in the organization. This investment aims to accelerate WPT’s expansion and bolster domestic pharmaceutical manufacturing capabilities.

Founded in 2003, Wilmington PharmaTech has established itself as a reliable partner for global drug developers. The company offers a comprehensive range of services that include discovery, clinical development, and commercial-scale manufacturing. WPT operates from a 54-acre campus in Newark, Delaware, which features two state-of-the-art facilities designed for current Good Manufacturing Practice (cGMP) and high potency API suites. Additionally, WPT maintains a research and development center in Suzhou, China.

Dr. Hui-Yin “Harry” Li, the founder and CEO of Wilmington PharmaTech, will retain a significant ownership stake and continue to lead the company alongside its existing management team. He expressed enthusiasm about the partnership, stating, “Together with Curewell Capital, we look forward to accelerating our growth strategy by leveraging our core competencies. We are committed to expanding our capabilities and capacity to better serve our global biopharmaceutical partners.”

The partnership with Curewell Capital is expected to provide substantial growth capital, enabling WPT to expand its manufacturing footprint. Michael Dal Bello, a partner at Curewell Capital, highlighted the importance of this investment, noting the rising demand for specialized pharmaceutical manufacturing within the United States. “Our investment will help WPT accelerate its next phase of growth amid strong market demand for dependable, high-quality capacity,” Dal Bello remarked.

This transaction positions Wilmington PharmaTech to take advantage of increasing domestic and international demand for advanced API development. The acquisition strengthens WPT’s role as a key manufacturing partner for biopharma innovators, allowing it to enhance its offerings and respond effectively to market needs.

With this investment, Wilmington PharmaTech aims to solidify its reputation as a leader in the pharmaceutical manufacturing sector, striving to meet the evolving requirements of its clients around the world. The collaboration with Curewell Capital marks a significant step forward for WPT as it prepares for the future of pharmaceutical production.